{"id":1866,"date":"2026-01-28T17:58:15","date_gmt":"2026-01-28T16:58:15","guid":{"rendered":"https:\/\/studienportal-eierstockkrebs.de\/platine-direncli-yumurtalik-kanseri-olan-hastalar-icin-haberler\/"},"modified":"2026-02-20T11:29:24","modified_gmt":"2026-02-20T10:29:24","slug":"platine-direncli-yumurtalik-kanseri-olan-hastalar-icin-haberler","status":"publish","type":"post","link":"https:\/\/studienportal-eierstockkrebs.de\/tr\/platine-direncli-yumurtalik-kanseri-olan-hastalar-icin-haberler\/","title":{"rendered":"Platine diren\u00e7li yumurtal\u0131k kanseri olan hastalar i\u00e7in haberler"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Hastalar i\u00e7in haberler<\/strong>
platine diren\u00e7li yumurtal\u0131k kanseri ile<\/span><\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u0130la\u00e7 \u015firketi Eli Lilly<\/b><\/span> k\u0131sa bir s\u00fcre \u00f6nce ABD G\u0131da ve \u0130la\u00e7 \u0130daresi<\/b><\/span> adl\u0131 yeni bir ila\u00e7 i\u00e7in ABD G\u0131da ve \u0130la\u00e7 Dairesi’nden (FDA) \u00c7\u0131\u011f\u0131r A\u00e7an Terapi Atamas\u0131<\/i> alm\u0131\u015ft\u0131r. sofetabart mipitecan<\/b><\/span> Sofetabart mipitecan adl\u0131 yeni bir ila\u00e7 i\u00e7in. Bu unvan sadece bir aktif maddenin ciddi bir hastal\u0131kta daha \u00f6nce mevcut olan tedavilerden \u00f6nemli \u00f6l\u00e7\u00fcde daha iyi sonu\u00e7lar verebilece\u011fine dair ilk belirtileri g\u00f6stermesi halinde verilir. <\/p>

Sofetabart mipitecan nedir?<\/b><\/span><\/p>

Sofetabart mipitecan<\/i>, antikor-ila\u00e7 konjugat\u0131 (ADC)<\/b><\/span> olarak adland\u0131r\u0131lan ve spesifik olarak folik asit resept\u00f6r\u00fc alfa (FR\u03b1)<\/b><\/span> t\u00fcm\u00f6r h\u00fccrelerinde bulunur ve orada bir kemoterapi maddesi salg\u0131lar. Bu resept\u00f6r bir\u00e7ok yumurtal\u0131k t\u00fcm\u00f6r\u00fcnde g\u00fc\u00e7l\u00fc bir \u015fekilde bulunmaktad\u0131r ve bu da ilac\u0131n hedefe y\u00f6nelik bir etkiye sahip olmas\u0131n\u0131 sa\u011flayacakt\u0131r.
ASCO 2025 ve ESMO 2025 gibi b\u00fcy\u00fck kanser kongrelerinde sunulan ilk \u00e7al\u0131\u015fmalardan elde edilen \u00f6nceki sonu\u00e7lar, daha \u00f6nce bevacizumab<\/i> veya mirvetuximab soravtansine<\/i> gibi standart tedaviler alm\u0131\u015f hastalarda t\u00fcm\u00f6r yan\u0131t\u0131<\/b><\/span> oldu\u011funu g\u00f6stermi\u015ftir. Bug\u00fcne kadar elde edilen veriler de g\u00f6stermektedir ki yan etkiler y\u00f6netilebilir<\/b><\/span> ve ciddi akci\u011fer sorunlar\u0131, sinir hasar\u0131 veya ciddi g\u00f6z hasar\u0131 <\/b>nadiren meydana gelmi\u015ftir.<\/p>

FDA tan\u0131m\u0131 ne anlama geliyor?<\/b><\/span><\/p>

\u00c7\u0131\u011f\u0131r A\u00e7an Terapi Tan\u0131mlamas\u0131n\u0131n<\/i> amac\u0131 geli\u015ftirme s\u00fcrecini h\u0131zland\u0131r\u0131n<\/b><\/span> ve yetkililerle daha erken g\u00f6r\u00fc\u015fmeler yap\u0131lmas\u0131n\u0131 sa\u011flayacakt\u0131r. Bu kesin bir ruhsat g\u00f6stergesi olmasa da, bug\u00fcne kadar elde edilen sonu\u00e7lar\u0131n umut verici oldu\u011fu ve daha h\u0131zl\u0131 geli\u015ftirme ve test yapman\u0131n mant\u0131kl\u0131 g\u00f6r\u00fcnd\u00fc\u011f\u00fc anlam\u0131na gelmektedir. <\/p>

Faz 3 \u00e7al\u0131\u015fmas\u0131 FRAmework-01 yak\u0131nda Almanya’da ba\u015flayacak!<\/b><\/span><\/p>

Lilly, bu olumlu ara sonu\u00e7lara dayanarak FRAmework-01 adl\u0131 Faz 3 \u00e7al\u0131\u015fmas\u0131<\/b><\/span> ba\u015flat\u0131lm\u0131\u015ft\u0131r. Bu \u00e7al\u0131\u015fmada, sofetabart mipitecan<\/i> platine diren\u00e7li yumurtal\u0131k kanseri (PROC) olan hastalarda tek terapi<\/b><\/span> platine duyarl\u0131 yumurtal\u0131k kanseri (PSOC) olan hastalarda bevacizumab<\/i> ile kombinasyon halinde.
Almanya’daki denemenin 2026 bahar\u0131nda ba\u015flamas\u0131 planlanmaktad\u0131r. \u0130lkbahar 2026<\/b><\/span> ve hastalara, dahil edilme kriterlerini (\u00f6rn. platine duyarl\u0131 veya platine diren\u00e7li t\u00fcm\u00f6r tan\u0131s\u0131) kar\u015f\u0131lamalar\u0131 ko\u015fuluyla, devam etmekte olan bir faz 3 \u00e7al\u0131\u015fmas\u0131na kat\u0131lma f\u0131rsat\u0131 sunmaktad\u0131r. <\/p>

Sofetabart mipitecan<\/i>, tedavisi zor, platine diren\u00e7li yumurtal\u0131k kanserinde, \u00f6zellikle de art\u0131k di\u011fer tedavilere yan\u0131t vermeyen t\u00fcm\u00f6rlerde etkili olabilecek umut verici bir ila\u00e7t\u0131r ve bu nedenle potansiyel yeni bir terap\u00f6tik se\u00e7enektir.<\/p>

Yeni Faz 3 \u00e7al\u0131\u015fmas\u0131 FRAmework-01 ile, daha sonra ruhsat verilmeden \u00f6nce Almanya’da uluslararas\u0131 bir \u00e7al\u0131\u015fmaya kat\u0131lma \u015fans\u0131<\/b><\/span> var. \u00c7al\u0131\u015fma ba\u015flar ba\u015flamaz \u00e7al\u0131\u015fma portal\u0131m\u0131zda daha fazla bilgi bulacaks\u0131n\u0131z! <\/p>

Kaynak:<\/strong> <\/span>Lilly’den bas\u0131n a\u00e7\u0131klamas\u0131<\/a> (makale \u0130ngilizcedir)<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Hastalar i\u00e7in haberlerplatine diren\u00e7li yumurtal\u0131k kanseri ile \u0130la\u00e7 \u015firketi Eli Lilly k\u0131sa bir s\u00fcre \u00f6nce ABD G\u0131da ve \u0130la\u00e7 \u0130daresi adl\u0131 yeni bir ila\u00e7 i\u00e7in ABD G\u0131da ve \u0130la\u00e7 Dairesi’nden (FDA) \u00c7\u0131\u011f\u0131r A\u00e7an Terapi Atamas\u0131 alm\u0131\u015ft\u0131r. sofetabart mipitecan Sofetabart mipitecan adl\u0131 yeni bir ila\u00e7 i\u00e7in. Bu unvan sadece bir aktif maddenin ciddi bir hastal\u0131kta daha […]<\/p>\n","protected":false},"author":5,"featured_media":2401,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[49],"tags":[],"class_list":["post-1866","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-haberler"],"acf":[],"_links":{"self":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/posts\/1866","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/comments?post=1866"}],"version-history":[{"count":3,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/posts\/1866\/revisions"}],"predecessor-version":[{"id":1870,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/posts\/1866\/revisions\/1870"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/media\/2401"}],"wp:attachment":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/media?parent=1866"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/categories?post=1866"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/tags?post=1866"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}